Sales@medsciencepharm.com    +86-396-2967988
Cont

Have any Questions?

+86-396-2967988

Jul 10, 2025

Industry overview on Urokinase

What is Urokinase?

Urokinase is an enzyme that activates plasminogen to form plasmin, which in turn breaks down fibrin, a key component of blood clots. It's also known as urokinase-type plasminogen activator (uPA).

 

Medical Uses

Urokinase is primarily used to:

  • Treat acute massive pulmonary embolism (PE) – especially when the patient is hemodynamically unstable.
  • Clear occluded intravenous or dialysis catheters (low-dose versions are often used for this purpose).
  • Treat deep vein thrombosis (DVT) or peripheral arterial occlusion (less common now due to newer agents).

 

Industry overview on Urokinase

 

Market Size & Growth Projections

  • Fortune Business Insights indicates urokinase market growth driven by rising thromboembolic disorders (e.g., DVT, pulmonary embolism), citing about 895,000 U.S. cases in 2023.
  • Business Research Insights forecasts the global urokinase market expanding from USD 0.52 billion in 2025 to USD 0.72 billion by 2034, with substantial R&D exploring new applications beyond traditional clot disorders.
  • Prospect Research presents a more modest estimate: USD 46 million in 2022, with projected growth to USD 65 million by 2029 at ~5% CAGR.
  • Allied Market Research offers a more expansive outlook: USD 1.8 billion in 2023, growing to USD 3.1 billion by 2033, at a CAGR of ~5.7%, fueled by cardiovascular disease prevalence, an aging population, and biotech investments. 
  • The Business Research Company reports growth from USD 1.7 billion (2024) to USD 1.81 billion (2025)-~6% growth-forecasting USD 2.26 billion by 2029, driven by stroke/PE prevalence, personalized medicine trends, AI integration, and rising obesity rates. 
  • Market.us reports that urokinase for injection generated ~US$ 141.1 million in 2023, forecasted to reach ~US$ 199 million by 2033 (+3.5% CAGR). 

 

Key Market Drivers & Growth Catalysts

  • Rising prevalence of thrombotic and cardiovascular conditions-including deep vein thrombosis, pulmonary embolism, heart attacks, and strokes-fuels demand for urokinase as a clot-dissolving agent. 
  • Aging population worldwide is increasing susceptibility to cardiovascular diseases, boosting demand for thrombolytic treatments like urokinase. 
  • Expanding therapeutic potential: Research is exploring urokinase applications beyond thrombosis-such as stroke recovery, catheter clearance, vascular occlusions, and even cancer diagnostics/therapy (e.g., targeting uPA/uPAR pathways).
  • Advanced formulations & delivery: Innovations such as combination therapies, biosimilars, and solution-based injectables are gaining traction due to convenience and efficacy. 

 

Restraints & Challenges

  • Bleeding risk: Significant hemorrhagic side effects restrict urokinase to monitored hospital environments, limiting broader outpatient use.
  • Regulatory and cost hurdles: Complex approval pathways and high production costs for biologics constrain market expansion.

 

Market Segmentation & Product Forms

 

By type:

  • Options include powder (often reconstituted) and solution/injection forms.
  • Market.us notes solutions held ~68.5% share in 2023 due to prep convenience and reduced error risk.
  • Some reports indicate powder still represents a dominant segment-e.g., ~92% by volume in certain definitions.

By end-user: Hospitals dominate adoption (~60–78%), given the urgent and monitored nature of thrombolytic therapy. 

 

Regional Dynamics

  • North America leads globally, contributing about 40–41% of revenue/share, supported by advanced healthcare infrastructure and high cardiovascular disease burden. 
  • Asia-Pacific is the fastest-growing region, driven by rising thrombotic disease awareness, increasing geriatric demographics, and healthcare improvements in markets like China and India.
  • Europe maintains stable growth, propelled by an aging population and expanding clinical applications. 
  • China is a standout-accounting for ~56% of global urokinase volume in some reports, with key manufacturers including Syner‑Med, LIVZON, Wanhua Biochem, Techpool, among others. 

 

Competitive Landscape

  • Major players include: Syner‑Med, LIVZON, Wanhua Biochem, Jiangxi Haoran Bio‑Pharma, Techpool, NDpharm, Cadila Healthcare, Microsystems, Taj Pharma, ImaRx, and global pharmaceutical giants like Pfizer, Abbott, Roche, Merck, Sanofi, and Teva. 
  • China-based firms and U.S. innovators jointly supply over half of global urokinase-often through novel formulations and catheter-based delivery technologies. 
  • Strategic alliances are key-for instance, MBX Biosciences partnered with Sequel Pharma in 2023 to reintroduce Kinlytic (urokinase) for catheter clearance, enhancing product access and compliance. 

 

Summary Table

Category Insights
Market Value & Forecast Range: USD 0.05–1.8 billion today; projected USD 0.7–3.1 billion by early 2030s-highlighting varied estimates by source.
Primary Use Cases Established in DVT, pulmonary embolism, myocardial infarction, catheter clearance, pleural effusions. Emerging exploration in stroke, vascular occlusion, cancer, and more.
Form & Delivery Predominantly hospital-use solutions and powders; innovating toward ready-to-use injectables, biosimilars, and combo therapies.
Region Highlights North America leads; Asia-Pacific fastest-growing; Europe consistent; China significant producer.
Competition & Strategy Mix of generics & big pharma; strong Chinese manufacturing; strategic collaborations to expand indications and access.
Growth Drivers Aging populations, rising CVD/thrombotic events, R&D, biotech advances.
Risks & Constraints Bleeding complications, regulatory cost hurdles, high production complexity.

 

 

Final Thoughts

The urokinase API industry remains crucial for thrombolytic therapy, with robust growth underpinned by demographic trends, cardiovascular disease prevalence, and research expansion. Regional growth is nuanced-North America dominates today, while Asia-Pacific is rapidly rising. Market expansion is tempered by safety and regulatory complexity, but innovation in formulations, partnerships, and new applications promise diversification.

 

Send Inquiry